Volition Sponsors Symposium on Nu.Q NETs Plasma Biomarker for Hidradenitis Suppurativa Treatment
ByAinvest
Wednesday, Feb 4, 2026 8:46 am ET1min read
VNRX--
VolitionRx Limited sponsors a symposium at the European Hidradenitis Suppurativa Foundation Conference to present data on its Nu.Q® NETs assay in patient management for Hidradenitis Suppurativa. The assay can classify patients and guide treatment selection and modification. The study demonstrates the potential of Nu.Q® NETs as a biomarker for ongoing and future clinical studies, aiming to guide treatment initiation and cessation. The market opportunity for such indications is significant, with a Total Addressable Market of $3.8 billion.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet